A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

• Status: RECRUITING
• Trial end date: 2029-10-08

Summary

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Treatments: 130-nm albumin-bound paclitaxel; Carboplatin; Paclitaxel; pembrolizumab